12/4/2024

Janusmed kön och genus

Janusmed kön och genus – Atripla

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Efavirenz

Efavirenz

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. Efavirenz Teva (efavirenz). Summary of Product Characteristics. European Medicines Agency (EMA); 2013.

  2. Nyakutira C, Röshammar D, Chigutsa E, Chonzi P, Ashton M, Nhachi C et al. High prevalence of the CYP2B6 516G-->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol. 2008;64(4):357-65.

  3. Anderson GD. Gender differences in pharmacological response. Int Rev Neurobiol. 2008;83(0):1-10.

  4. Nicolson TJ, Mellor HR, Roberts RR. Gender differences in drug toxicity. Trends Pharmacol Sci. 2010;31:108-14.

  5. Dhoro M, Zvada S, Ngara B, Nhachi C, Kadzirange G, Chonzi P et al. CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe. BMC Pharmacol Toxicol. 2015;16(0):4.

  6. Mukonzo JK, Nanzigu S, Rekić D, Waako P, Röshammar D, Ashton M et al. HIV/AIDS patients display lower relative bioavailability of efavirenz than healthy subjects. Clin Pharmacokinet. 2011;50(8):531-40.

  7. Burger D, van der Heiden I, la Porte C, van der Ende M, Groeneveld P, Richter C et al. Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. Br J Clin Pharmacol. 2006;61(2):148-54.

  8. Ibarra M, Magallanes L, Lorier M, Vázquez M, Fagiolino P. Sex-by-formulation interaction assessed through a bioequivalence study of efavirenz tablets. Eur J Pharm Sci. 2016;85(1):106-11.

  9. Wester CW, Stitelman OM, deGruttola V, Bussmann H, Marlink RG, van der Laan MJ. Effect modification by sex and baseline CD4+ cell count among adults receiving combination antiretroviral therapy in Botswana: results from a clinical trial. AIDS Res Hum Retroviruses. 2012;28(9):981-8.

  10. Puthanakit T, Kerr S, Ananworanich J, Bunupuradah T, Boonrak P, Sirisanthana V. Pattern and predictors of immunologic recovery in human immunodeficiency virus-infected children receiving non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy. Pediatr Infect Dis J. 2009;28(6):488-92.

  11. Chawana TD, Reid A, Bwakura T, Gavi S, Nhachi CF. Factors influencing treatment failure in HIV positive adult patients on first line antiretroviral therapy. Cent Afr J Med. 2014;60(5):29-36.

  12. Bienczak A, Denti P, Cook A, Wiesner L, Mulenga V, Kityo C et al. Plasma Efavirenz Exposure, Sex, and Age Predict Virological Response in HIV-Infected African Children. J Acquir Immune Defic Syndr. 2016;73(2):161-8.

  13. Annan NT, Nelson M, Mandalia S, Bower M, Gazzard BG, Stebbing J. The nucleoside backbone affects durability of efavirenz- or nevirapine-based highly active antiretroviral therapy in antiretroviral-naive individuals. J Acquir Immune Defic Syndr. 2009;51(2):140-6.

  14. Hodder S, Arasteh K, De Wet J, Gathe J, Gold J, Kumar P et al. Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE. HIV Med. 2012;13(7):406-15.

  15. Castelnuovo B, Kiragga A, Mubiru F, Kambugu A, Kamya M, Reynolds SJ. First-line antiretroviral therapy durability in a 10-year cohort of naïve adults started on treatment in Uganda. J Int AIDS Soc. 2016;19(1):20773.

  16. Kuritzkes DR, Ribaudo HJ, Squires KE, Koletar SL, Santana J, Riddler SA et al. Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s. J Infect Dis. 2007;195(8):1169-76.

  17. Johnson M, Walmsley S, Haberl A. A systematic review of the use of atazanavir in women infected with HIV-1. Antivir Ther. 2014;19(3):293-307.

  18. Hunt GM, Dokubo EK, Takuva S, de Oliveira T, Ledwaba J, Dube N et al. Rates of virological suppression and drug resistance in adult HIV-1-positive patients attending primary healthcare facilities in KwaZulu-Natal, South Africa. J Antimicrob Chemother. 2017;72(11):3141-3148.

  19. Kumar PN, Rodriguez-French A, Thompson MA, Tashima KT, Averitt D, Wannamaker PG et al. A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity. HIV Med. 2006;7(2):85-98.

  20. Smith KY, Tierney C, Mollan K, Venuto CS, Budhathoki C, Ma Q et al. Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine. Clin Infect Dis. 2014;58(4):555-63.

  21. Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O et al. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study. PLoS Med. 2015;12(3):e1001809.

  22. Dlamini J, Ledwaba L, Mokwena N, Mokhathi T, Orsega S, Tsoku M et al. Lactic acidosis and symptomatic hyperlactataemia in a randomized trial of first-line therapy in HIV-infected adults in South Africa. Antivir Ther. 2011;16(4):605-9.

  23. Dhoro M, Ngara B, Kadzirange G, Nhachi C, Masimirembwa C. Genetic variants of drug metabolizing enzymes and drug transporter (ABCB1) as possible biomarkers for adverse drug reactions in an HIV/AIDS cohort in Zimbabwe. Curr HIV Res. 2013;11(6):481-90.

  24. Martín-Carbonero L, Núñez M, González-Lahoz J, Soriano V. Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine. HIV Clin Trials. 2003;4(2):115-20.

  25. Sonderup MW, Maughan D, Gogela N, Setshedi M, Wainwright H, Meintjes G et al. Identification of a novel and severe pattern of efavirenz drug-induced liver injury in South Africa. AIDS. 2016;30(9):1483-5.

  26. Sanne I, Mommeja-Marin H, Hinkle J, Bartlett JA, Lederman MM, Maartens G et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis. 2005;191(6):825-9.

  27. Ocama P, Castelnuovo B, Kamya MR, Kirk GD, Reynolds SJ, Kiragga A et al. Low frequency of liver enzyme elevation in HIV-infected patients attending a large urban treatment centre in Uganda. Int J STD AIDS. 2010;21(8):553-7.

  28. Tashima KT, Bausserman L, Alt EN, Aznar E, Flanigan TP. Lipid changes in patients initiating efavirenz- and indinavir-based antiretroviral regimens. HIV Clin Trials. 2003;4(1):29-36.

  29. Ombeni W, Kamuhabwa AR. Lipid Profile in HIV-Infected Patients Using First-Line Antiretroviral Drugs. J Int Assoc Provid AIDS Care. 2015;15(2):164-71.

  30. Dave JA, Lambert EV, Badri M, West S, Maartens G, Levitt NS. Effect of nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy on dysglycemia and insulin sensitivity in South African HIV-infected patients. J Acquir Immune Defic Syndr. 2011;57(4):284-9.

  31. Firnhaber C, Smeaton LM, Grinsztejn B, Lalloo U, Faesen S, Samaneka W et al. Differences in antiretroviral safety and efficacy by sex in a multinational randomized clinical trial. HIV Clin Trials. 2015;16(3):89-99.

  32. Svedhem-Johansson V, Pugliese P, Brockmeyer NH, Thalme A, Michalik C, Esser S et al. Long-term gender-based outcomes for atazanavir/ritonavir (ATV/r)- containing regimens in treatment-experienced patients with HIV. Curr HIV Res. 2013;11(4):333-41.

  33. Eluwa GI, Badru T, Agu KA, Akpoigbe KJ, Chabikuli O, Hamelmann C. Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria. BMC Clin Pharmacol. 2012;12(1):7.

  34. Bandeira ACPCS, Elias DBD, Cavalcante MG, Lima DGL, Távora LGF. Antiretroviral changes during the first year of therapy. Rev Assoc Med Bras (1992). 2017;63(7):606-612.

  35. Spire B, Carrieri P, Garzot MA, L'henaff M, Obadia Y, TRT-5 Group. Factors associated with efavirenz discontinuation in a large community-based sample of patients. AIDS Care. 2004;16(5):558-64.

  36. Fabbiani M, Zaccarelli M, Grima P, Prosperi M, Fanti I, Colafigli M et al. Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients. BMC Infect Dis. 2014;14(1):26.

  37. Shikuma CM, Ribaudo HJ, Zheng Y, Gulick RM, Meyer WA, Tashima KT et al. Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals. AIDS Res Hum Retroviruses. 2011;27(5):461-8.

  38. Else LJ, Taylor S, Back DJ, Khoo SH. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. Antivir Ther. 2011;16(8):1149-67.

  39. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2017 [cited 2018-07-24.]

  1. Efavirenz Teva (efavirenz). Summary of Product Characteristics. European Medicines Agency (EMA); 2013.
  2. Nyakutira C, Röshammar D, Chigutsa E, Chonzi P, Ashton M, Nhachi C et al. High prevalence of the CYP2B6 516G-->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol. 2008;64(4):357-65.
  3. Anderson GD. Gender differences in pharmacological response. Int Rev Neurobiol. 2008;83(0):1-10.
  4. Nicolson TJ, Mellor HR, Roberts RR. Gender differences in drug toxicity. Trends Pharmacol Sci. 2010;31:108-14.
  5. Dhoro M, Zvada S, Ngara B, Nhachi C, Kadzirange G, Chonzi P et al. CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe. BMC Pharmacol Toxicol. 2015;16(0):4.
  6. Mukonzo JK, Nanzigu S, Rekić D, Waako P, Röshammar D, Ashton M et al. HIV/AIDS patients display lower relative bioavailability of efavirenz than healthy subjects. Clin Pharmacokinet. 2011;50(8):531-40.
  7. Burger D, van der Heiden I, la Porte C, van der Ende M, Groeneveld P, Richter C et al. Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. Br J Clin Pharmacol. 2006;61(2):148-54.
  8. Ibarra M, Magallanes L, Lorier M, Vázquez M, Fagiolino P. Sex-by-formulation interaction assessed through a bioequivalence study of efavirenz tablets. Eur J Pharm Sci. 2016;85(1):106-11.
  9. Wester CW, Stitelman OM, deGruttola V, Bussmann H, Marlink RG, van der Laan MJ. Effect modification by sex and baseline CD4+ cell count among adults receiving combination antiretroviral therapy in Botswana: results from a clinical trial. AIDS Res Hum Retroviruses. 2012;28(9):981-8.
  10. Puthanakit T, Kerr S, Ananworanich J, Bunupuradah T, Boonrak P, Sirisanthana V. Pattern and predictors of immunologic recovery in human immunodeficiency virus-infected children receiving non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy. Pediatr Infect Dis J. 2009;28(6):488-92.
  11. Chawana TD, Reid A, Bwakura T, Gavi S, Nhachi CF. Factors influencing treatment failure in HIV positive adult patients on first line antiretroviral therapy. Cent Afr J Med. 2014;60(5):29-36.
  12. Bienczak A, Denti P, Cook A, Wiesner L, Mulenga V, Kityo C et al. Plasma Efavirenz Exposure, Sex, and Age Predict Virological Response in HIV-Infected African Children. J Acquir Immune Defic Syndr. 2016;73(2):161-8.
  13. Annan NT, Nelson M, Mandalia S, Bower M, Gazzard BG, Stebbing J. The nucleoside backbone affects durability of efavirenz- or nevirapine-based highly active antiretroviral therapy in antiretroviral-naive individuals. J Acquir Immune Defic Syndr. 2009;51(2):140-6.
  14. Hodder S, Arasteh K, De Wet J, Gathe J, Gold J, Kumar P et al. Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE. HIV Med. 2012;13(7):406-15.
  15. Castelnuovo B, Kiragga A, Mubiru F, Kambugu A, Kamya M, Reynolds SJ. First-line antiretroviral therapy durability in a 10-year cohort of naïve adults started on treatment in Uganda. J Int AIDS Soc. 2016;19(1):20773.
  16. Kuritzkes DR, Ribaudo HJ, Squires KE, Koletar SL, Santana J, Riddler SA et al. Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s. J Infect Dis. 2007;195(8):1169-76.
  17. Johnson M, Walmsley S, Haberl A. A systematic review of the use of atazanavir in women infected with HIV-1. Antivir Ther. 2014;19(3):293-307.
  18. Hunt GM, Dokubo EK, Takuva S, de Oliveira T, Ledwaba J, Dube N et al. Rates of virological suppression and drug resistance in adult HIV-1-positive patients attending primary healthcare facilities in KwaZulu-Natal, South Africa. J Antimicrob Chemother. 2017;72(11):3141-3148.
  19. Kumar PN, Rodriguez-French A, Thompson MA, Tashima KT, Averitt D, Wannamaker PG et al. A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity. HIV Med. 2006;7(2):85-98.
  20. Smith KY, Tierney C, Mollan K, Venuto CS, Budhathoki C, Ma Q et al. Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine. Clin Infect Dis. 2014;58(4):555-63.
  21. Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O et al. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study. PLoS Med. 2015;12(3):e1001809.
  22. Dlamini J, Ledwaba L, Mokwena N, Mokhathi T, Orsega S, Tsoku M et al. Lactic acidosis and symptomatic hyperlactataemia in a randomized trial of first-line therapy in HIV-infected adults in South Africa. Antivir Ther. 2011;16(4):605-9.
  23. Dhoro M, Ngara B, Kadzirange G, Nhachi C, Masimirembwa C. Genetic variants of drug metabolizing enzymes and drug transporter (ABCB1) as possible biomarkers for adverse drug reactions in an HIV/AIDS cohort in Zimbabwe. Curr HIV Res. 2013;11(6):481-90.
  24. Martín-Carbonero L, Núñez M, González-Lahoz J, Soriano V. Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine. HIV Clin Trials. 2003;4(2):115-20.
  25. Sonderup MW, Maughan D, Gogela N, Setshedi M, Wainwright H, Meintjes G et al. Identification of a novel and severe pattern of efavirenz drug-induced liver injury in South Africa. AIDS. 2016;30(9):1483-5.
  26. Sanne I, Mommeja-Marin H, Hinkle J, Bartlett JA, Lederman MM, Maartens G et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis. 2005;191(6):825-9.
  27. Ocama P, Castelnuovo B, Kamya MR, Kirk GD, Reynolds SJ, Kiragga A et al. Low frequency of liver enzyme elevation in HIV-infected patients attending a large urban treatment centre in Uganda. Int J STD AIDS. 2010;21(8):553-7.
  28. Tashima KT, Bausserman L, Alt EN, Aznar E, Flanigan TP. Lipid changes in patients initiating efavirenz- and indinavir-based antiretroviral regimens. HIV Clin Trials. 2003;4(1):29-36.
  29. Ombeni W, Kamuhabwa AR. Lipid Profile in HIV-Infected Patients Using First-Line Antiretroviral Drugs. J Int Assoc Provid AIDS Care. 2015;15(2):164-71.
  30. Dave JA, Lambert EV, Badri M, West S, Maartens G, Levitt NS. Effect of nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy on dysglycemia and insulin sensitivity in South African HIV-infected patients. J Acquir Immune Defic Syndr. 2011;57(4):284-9.
  31. Firnhaber C, Smeaton LM, Grinsztejn B, Lalloo U, Faesen S, Samaneka W et al. Differences in antiretroviral safety and efficacy by sex in a multinational randomized clinical trial. HIV Clin Trials. 2015;16(3):89-99.
  32. Svedhem-Johansson V, Pugliese P, Brockmeyer NH, Thalme A, Michalik C, Esser S et al. Long-term gender-based outcomes for atazanavir/ritonavir (ATV/r)- containing regimens in treatment-experienced patients with HIV. Curr HIV Res. 2013;11(4):333-41.
  33. Eluwa GI, Badru T, Agu KA, Akpoigbe KJ, Chabikuli O, Hamelmann C. Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria. BMC Clin Pharmacol. 2012;12(1):7.
  34. Bandeira ACPCS, Elias DBD, Cavalcante MG, Lima DGL, Távora LGF. Antiretroviral changes during the first year of therapy. Rev Assoc Med Bras (1992). 2017;63(7):606-612.
  35. Spire B, Carrieri P, Garzot MA, L'henaff M, Obadia Y, TRT-5 Group. Factors associated with efavirenz discontinuation in a large community-based sample of patients. AIDS Care. 2004;16(5):558-64.
  36. Fabbiani M, Zaccarelli M, Grima P, Prosperi M, Fanti I, Colafigli M et al. Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients. BMC Infect Dis. 2014;14(1):26.
  37. Shikuma CM, Ribaudo HJ, Zheng Y, Gulick RM, Meyer WA, Tashima KT et al. Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals. AIDS Res Hum Retroviruses. 2011;27(5):461-8.
  38. Else LJ, Taylor S, Back DJ, Khoo SH. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. Antivir Ther. 2011;16(8):1149-67.
  39. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2017 [cited 2018-07-24.]
A A
A A

Emtricitabin

Emtricitabin

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. Emtriva (emtricitabin). Summary of Product Characteristics. European Medicines Agency (EMA); 2018.

  2. Hodder S, Arasteh K, De Wet J, Gathe J, Gold J, Kumar P et al. Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE. HIV Med. 2012;13(7):406-15.

  3. Squires KE, Johnson M, Yang R, Uy J, Sheppard L, Absalon J et al. Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study. J Antimicrob Chemother. 2011;66(2):363-70.

  4. Svedhem-Johansson V, Pugliese P, Brockmeyer NH, Thalme A, Michalik C, Esser S et al. Long-term gender-based outcomes for atazanavir/ritonavir (ATV/r)- containing regimens in treatment-experienced patients with HIV. Curr HIV Res. 2013;11(4):333-41.

  5. Sanne I, Mommeja-Marin H, Hinkle J, Bartlett JA, Lederman MM, Maartens G et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis. 2005;191(6):825-9.

  6. Koethe JR, Jenkins CA, Petucci C, Culver J, Shepherd BE, Sterling TR. Superior Glucose Tolerance and Metabolomic Profiles, Independent of Adiposity, in HIV-Infected Women Compared With Men on Antiretroviral Therapy. Medicine (Baltimore). 2016;95(19):e3634.

  7. Eaton EF, Tamhane A, Davy-Mendez T, Mathews WC, Moore RD, Saag MS et al. Trends in antiretroviral therapy prescription, durability and modification: new drugs, more changes, but less failure. AIDS. 2018;32(3):347-355.

  8. Firnhaber C, Smeaton LM, Grinsztejn B, Lalloo U, Faesen S, Samaneka W et al. Differences in antiretroviral safety and efficacy by sex in a multinational randomized clinical trial. HIV Clin Trials. 2015;16(3):89-99.

  9. Else LJ, Taylor S, Back DJ, Khoo SH. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. Antivir Ther. 2011;16(8):1149-67.

  10. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2017 [cited 2018-07-24.]

  1. Emtriva (emtricitabin). Summary of Product Characteristics. European Medicines Agency (EMA); 2018.
  2. Hodder S, Arasteh K, De Wet J, Gathe J, Gold J, Kumar P et al. Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE. HIV Med. 2012;13(7):406-15.
  3. Squires KE, Johnson M, Yang R, Uy J, Sheppard L, Absalon J et al. Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study. J Antimicrob Chemother. 2011;66(2):363-70.
  4. Svedhem-Johansson V, Pugliese P, Brockmeyer NH, Thalme A, Michalik C, Esser S et al. Long-term gender-based outcomes for atazanavir/ritonavir (ATV/r)- containing regimens in treatment-experienced patients with HIV. Curr HIV Res. 2013;11(4):333-41.
  5. Sanne I, Mommeja-Marin H, Hinkle J, Bartlett JA, Lederman MM, Maartens G et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis. 2005;191(6):825-9.
  6. Koethe JR, Jenkins CA, Petucci C, Culver J, Shepherd BE, Sterling TR. Superior Glucose Tolerance and Metabolomic Profiles, Independent of Adiposity, in HIV-Infected Women Compared With Men on Antiretroviral Therapy. Medicine (Baltimore). 2016;95(19):e3634.
  7. Eaton EF, Tamhane A, Davy-Mendez T, Mathews WC, Moore RD, Saag MS et al. Trends in antiretroviral therapy prescription, durability and modification: new drugs, more changes, but less failure. AIDS. 2018;32(3):347-355.
  8. Firnhaber C, Smeaton LM, Grinsztejn B, Lalloo U, Faesen S, Samaneka W et al. Differences in antiretroviral safety and efficacy by sex in a multinational randomized clinical trial. HIV Clin Trials. 2015;16(3):89-99.
  9. Else LJ, Taylor S, Back DJ, Khoo SH. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. Antivir Ther. 2011;16(8):1149-67.
  10. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2017 [cited 2018-07-24.]
A A
A A

Tenofovir

Tenofovir

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. Pruvost A, Negredo E, Théodoro F, Puig J, Levi M, Ayen R et al. Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir. Antimicrob Agents Chemother. 2009;53(5):1937-43.

  2. Viread (tenofovir disoproxil). Summary of Product Characteristics. European Medicines Agency (EMA); 2018.

  3. Vemlidy (tenofovir alafenamide). Summary of Product Characteristics. European Medicines Agency (EMA); 2018.

  4. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010;51(5):496-505.

  5. Hodder S, Arasteh K, De Wet J, Gathe J, Gold J, Kumar P et al. Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE. HIV Med. 2012;13(7):406-15.

  6. Chawana TD, Reid A, Bwakura T, Gavi S, Nhachi CF. Factors influencing treatment failure in HIV positive adult patients on first line antiretroviral therapy. Cent Afr J Med. 2014;60(5):29-36.

  7. Aberra H, Desalegn H, Berhe N, Medhin G, Stene-Johansen K, Gundersen SG et al. Early experiences from one of the first treatment programs for chronic hepatitis B in sub-Saharan Africa. BMC Infect Dis. 2017;17(1):438.

  8. Vinikoor MJ, Sinkala E, Chilengi R, Mulenga LB, Chi BH, Zyambo Z et al. Impact of Antiretroviral Therapy on Liver Fibrosis Among Human Immunodeficiency Virus-Infected Adults With and Without HBV Coinfection in Zambia. Clin Infect Dis. 2017;64(10):1343-1349.

  9. Papatheodoridis G, Dalekos G, Sypsa V, Yurdaydin C, Buti M, Goulis J et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol. 2016;64(4):800-6.

  10. Tordato F, Cozzi Lepri A, Cicconi P, De Luca A, Antinori A, Colangeli V et al. Evaluation of glomerular filtration rate in HIV-1-infected patients before and after combined antiretroviral therapy exposure. HIV Med. 2011;12(1):4-13.

  11. Poizot-Martin I, Solas C, Allemand J, Obry-Roguet V, Pradel V, Bregigeon S, Faucher O, Lacarelle B. Renal impairment in patients receiving a tenofovir-cART regimen: Impact of tenofovir trough concentration. J Acquir Immune Defic Syndr 2012 Nov 28;

  12. Pinto Neto LF, Bassetti BR, Fraga IH, Oliveira Santos CR, Ximenes PD, Miranda AE. Nephrotoxicity during tenofovir treatment: a three-year follow-up study in a Brazilian reference clinic. Braz J Infect Dis. 2016;20(1):14-8.

  13. Lim Y, Lyall H, Foster C. Tenofovir-Associated Nephrotoxicity in Children with Perinatally-Acquired HIV Infection: A Single-Centre Cohort Study. Clin Drug Investig. 2015;35(5):327-33.

  14. Luque A, Hulse S, Wang D, Shahzad U, Tanzman E, Antenozzi S et al. Assessment of adverse events associated with antiretroviral regimens for postexposure prophylaxis for occupational and nonoccupational exposures to prevent transmission of human immunodeficiency virus. Infect Control Hosp Epidemiol. 2007;28(6):695-701.

  15. Law M, Puls R, Cheng AK, Cooper DA, Carr A. Evaluation of the HIV lipodystrophy case definition in a placebo-controlled, 144-week study in antiretroviral-naive adults. Antivir Ther. 2006;11(2):179-86.

  16. Svedhem-Johansson V, Pugliese P, Brockmeyer NH, Thalme A, Michalik C, Esser S et al. Long-term gender-based outcomes for atazanavir/ritonavir (ATV/r)- containing regimens in treatment-experienced patients with HIV. Curr HIV Res. 2013;11(4):333-41.

  17. Klassen K, Martineau AR, Wilkinson RJ, Cooke G, Courtney AP, Hickson M. The effect of tenofovir on vitamin D metabolism in HIV-infected adults is dependent on sex and ethnicity. PLoS One. 2012;7(9):e44845.

  18. Koethe JR, Jenkins CA, Petucci C, Culver J, Shepherd BE, Sterling TR. Superior Glucose Tolerance and Metabolomic Profiles, Independent of Adiposity, in HIV-Infected Women Compared With Men on Antiretroviral Therapy. Medicine (Baltimore). 2016;95(19):e3634.

  19. Triantos C, Kalafateli M, Aggeletopoulou I, Mandellou M, Assimakopoulos S, Tselekouni P et al. Lactate serum concentrations during treatment with nucleos(t)ide analogues in hepatitis B with or without cirrhosis. Eur J Gastroenterol Hepatol. 2017;29(9):998-1003.

  20. Bandeira ACPCS, Elias DBD, Cavalcante MG, Lima DGL, Távora LGF. Antiretroviral changes during the first year of therapy. Rev Assoc Med Bras (1992). 2017;63(7):606-612.

  21. Ombeni W, Kamuhabwa AR. Lipid Profile in HIV-Infected Patients Using First-Line Antiretroviral Drugs. J Int Assoc Provid AIDS Care. 2015;15(2):164-71.

  22. Else LJ, Taylor S, Back DJ, Khoo SH. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. Antivir Ther. 2011;16(8):1149-67.

  23. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2017 [cited 2018-07-24.]

  1. Pruvost A, Negredo E, Théodoro F, Puig J, Levi M, Ayen R et al. Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir. Antimicrob Agents Chemother. 2009;53(5):1937-43.
  2. Viread (tenofovir disoproxil). Summary of Product Characteristics. European Medicines Agency (EMA); 2018.
  3. Vemlidy (tenofovir alafenamide). Summary of Product Characteristics. European Medicines Agency (EMA); 2018.
  4. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010;51(5):496-505.
  5. Hodder S, Arasteh K, De Wet J, Gathe J, Gold J, Kumar P et al. Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE. HIV Med. 2012;13(7):406-15.
  6. Chawana TD, Reid A, Bwakura T, Gavi S, Nhachi CF. Factors influencing treatment failure in HIV positive adult patients on first line antiretroviral therapy. Cent Afr J Med. 2014;60(5):29-36.
  7. Aberra H, Desalegn H, Berhe N, Medhin G, Stene-Johansen K, Gundersen SG et al. Early experiences from one of the first treatment programs for chronic hepatitis B in sub-Saharan Africa. BMC Infect Dis. 2017;17(1):438.
  8. Vinikoor MJ, Sinkala E, Chilengi R, Mulenga LB, Chi BH, Zyambo Z et al. Impact of Antiretroviral Therapy on Liver Fibrosis Among Human Immunodeficiency Virus-Infected Adults With and Without HBV Coinfection in Zambia. Clin Infect Dis. 2017;64(10):1343-1349.
  9. Papatheodoridis G, Dalekos G, Sypsa V, Yurdaydin C, Buti M, Goulis J et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol. 2016;64(4):800-6.
  10. Tordato F, Cozzi Lepri A, Cicconi P, De Luca A, Antinori A, Colangeli V et al. Evaluation of glomerular filtration rate in HIV-1-infected patients before and after combined antiretroviral therapy exposure. HIV Med. 2011;12(1):4-13.
  11. Poizot-Martin I, Solas C, Allemand J, Obry-Roguet V, Pradel V, Bregigeon S, Faucher O, Lacarelle B. Renal impairment in patients receiving a tenofovir-cART regimen: Impact of tenofovir trough concentration. J Acquir Immune Defic Syndr 2012 Nov 28;
  12. Pinto Neto LF, Bassetti BR, Fraga IH, Oliveira Santos CR, Ximenes PD, Miranda AE. Nephrotoxicity during tenofovir treatment: a three-year follow-up study in a Brazilian reference clinic. Braz J Infect Dis. 2016;20(1):14-8.
  13. Lim Y, Lyall H, Foster C. Tenofovir-Associated Nephrotoxicity in Children with Perinatally-Acquired HIV Infection: A Single-Centre Cohort Study. Clin Drug Investig. 2015;35(5):327-33.
  14. Luque A, Hulse S, Wang D, Shahzad U, Tanzman E, Antenozzi S et al. Assessment of adverse events associated with antiretroviral regimens for postexposure prophylaxis for occupational and nonoccupational exposures to prevent transmission of human immunodeficiency virus. Infect Control Hosp Epidemiol. 2007;28(6):695-701.
  15. Law M, Puls R, Cheng AK, Cooper DA, Carr A. Evaluation of the HIV lipodystrophy case definition in a placebo-controlled, 144-week study in antiretroviral-naive adults. Antivir Ther. 2006;11(2):179-86.
  16. Svedhem-Johansson V, Pugliese P, Brockmeyer NH, Thalme A, Michalik C, Esser S et al. Long-term gender-based outcomes for atazanavir/ritonavir (ATV/r)- containing regimens in treatment-experienced patients with HIV. Curr HIV Res. 2013;11(4):333-41.
  17. Klassen K, Martineau AR, Wilkinson RJ, Cooke G, Courtney AP, Hickson M. The effect of tenofovir on vitamin D metabolism in HIV-infected adults is dependent on sex and ethnicity. PLoS One. 2012;7(9):e44845.
  18. Koethe JR, Jenkins CA, Petucci C, Culver J, Shepherd BE, Sterling TR. Superior Glucose Tolerance and Metabolomic Profiles, Independent of Adiposity, in HIV-Infected Women Compared With Men on Antiretroviral Therapy. Medicine (Baltimore). 2016;95(19):e3634.
  19. Triantos C, Kalafateli M, Aggeletopoulou I, Mandellou M, Assimakopoulos S, Tselekouni P et al. Lactate serum concentrations during treatment with nucleos(t)ide analogues in hepatitis B with or without cirrhosis. Eur J Gastroenterol Hepatol. 2017;29(9):998-1003.
  20. Bandeira ACPCS, Elias DBD, Cavalcante MG, Lima DGL, Távora LGF. Antiretroviral changes during the first year of therapy. Rev Assoc Med Bras (1992). 2017;63(7):606-612.
  21. Ombeni W, Kamuhabwa AR. Lipid Profile in HIV-Infected Patients Using First-Line Antiretroviral Drugs. J Int Assoc Provid AIDS Care. 2015;15(2):164-71.
  22. Else LJ, Taylor S, Back DJ, Khoo SH. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. Antivir Ther. 2011;16(8):1149-67.
  23. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2017 [cited 2018-07-24.]